Teacher Retirement System of Texas Has $100.08 Million Stake in Boston Scientific Corporation $BSX

Teacher Retirement System of Texas lifted its position in Boston Scientific Corporation (NYSE:BSX) by 6.9% in the second quarter, HoldingsChannel.com reports. The firm owned 931,793 shares of the medical equipment provider’s stock after acquiring an additional 60,144 shares during the period. Teacher Retirement System of Texas’ holdings in Boston Scientific were worth $100,084,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of BSX. Brighton Jones LLC grew its position in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. GAMMA Investing LLC grew its position in Boston Scientific by 17.2% in the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider’s stock valued at $2,578,000 after acquiring an additional 3,745 shares during the period. Golden State Wealth Management LLC grew its position in Boston Scientific by 37.0% in the first quarter. Golden State Wealth Management LLC now owns 1,674 shares of the medical equipment provider’s stock valued at $169,000 after acquiring an additional 452 shares during the period. Perigon Wealth Management LLC grew its position in Boston Scientific by 7.9% in the first quarter. Perigon Wealth Management LLC now owns 13,532 shares of the medical equipment provider’s stock valued at $1,365,000 after acquiring an additional 996 shares during the period. Finally, Diversified Trust Co grew its position in Boston Scientific by 15.9% in the first quarter. Diversified Trust Co now owns 5,236 shares of the medical equipment provider’s stock valued at $528,000 after acquiring an additional 718 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on BSX. Wells Fargo & Company upped their price target on Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a research report on Thursday. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research report on Friday. The Goldman Sachs Group reiterated a “buy” rating and issued a $124.00 price target on shares of Boston Scientific in a research report on Wednesday. Robert W. Baird increased their target price on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $118.00 to $125.00 in a report on Monday, September 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $123.77.

Insider Activity at Boston Scientific

In related news, Director Yoshiaki Fujimori sold 2,901 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 170,214 shares of company stock worth $17,548,337 over the last 90 days. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX stock opened at $101.08 on Monday. The stock’s fifty day moving average is $101.14 and its 200-day moving average is $102.12. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a market capitalization of $149.78 billion, a PE ratio of 54.06, a PEG ratio of 2.04 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.